Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

The Limitations of the Rheumatogenic Concept for Group A Streptococcus: Systematic Review and Genetic Analysis.

de Crombrugghe G, Baroux N, Botteaux A, Moreland NJ, Williamson DA, Steer AC, Smeesters PR.

Clin Infect Dis. 2019 Jul 23. pii: ciz425. doi: 10.1093/cid/ciz425. [Epub ahead of print]

PMID:
31334754
2.

Author Correction: Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.

Davies MR, McIntyre L, Mutreja A, Lacey JA, Lees JA, Towers RJ, Duchêne S, Smeesters PR, Frost HR, Price DJ, Holden MTG, David S, Giffard PM, Worthing KA, Seale AC, Berkley JA, Harris SR, Rivera-Hernandez T, Berking O, Cork AJ, Torres RSLA, Lithgow T, Strugnell RA, Bergmann R, Nitsche-Schmitz P, Chhatwal GS, Bentley SD, Fraser JD, Moreland NJ, Carapetis JR, Steer AC, Parkhill J, Saul A, Williamson DA, Currie BJ, Tong SYC, Dougan G, Walker MJ.

Nat Genet. 2019 Aug;51(8):1295. doi: 10.1038/s41588-019-0482-z.

PMID:
31324894
3.

Understanding group A streptococcal pharyngitis and skin infections as causes of rheumatic fever: protocol for a prospective disease incidence study.

Bennett J, Moreland NJ, Oliver J, Crane J, Williamson DA, Sika-Paotonu D, Harwood M, Upton A, Smith S, Carapetis J, Baker MG.

BMC Infect Dis. 2019 Jul 17;19(1):633. doi: 10.1186/s12879-019-4126-9.

4.

Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.

Davies MR, McIntyre L, Mutreja A, Lacey JA, Lees JA, Towers RJ, Duchêne S, Smeesters PR, Frost HR, Price DJ, Holden MTG, David S, Giffard PM, Worthing KA, Seale AC, Berkley JA, Harris SR, Rivera-Hernandez T, Berking O, Cork AJ, Torres RSLA, Lithgow T, Strugnell RA, Bergmann R, Nitsche-Schmitz P, Chhatwal GS, Bentley SD, Fraser JD, Moreland NJ, Carapetis JR, Steer AC, Parkhill J, Saul A, Williamson DA, Currie BJ, Tong SYC, Dougan G, Walker MJ.

Nat Genet. 2019 Jun;51(6):1035-1043. doi: 10.1038/s41588-019-0417-8. Epub 2019 May 27. Erratum in: Nat Genet. 2019 Jul 19;:.

PMID:
31133745
5.

Group A Streptococcus T Antigens Have a Highly Conserved Structure Concealed under a Heterogeneous Surface That Has Implications for Vaccine Design.

Young PG, Raynes JM, Loh JM, Proft T, Baker EN, Moreland NJ.

Infect Immun. 2019 May 21;87(6). pii: e00205-19. doi: 10.1128/IAI.00205-19. Print 2019 Jun.

PMID:
30936156
6.

Streptococcal Serology in Acute Rheumatic Fever Patients: Findings From 2 High-income, High-burden Settings.

Jack S, Moreland NJ, Meagher J, Fittock M, Galloway Y, Ralph AP.

Pediatr Infect Dis J. 2019 Jan;38(1):e1-e6. doi: 10.1097/INF.0000000000002190.

PMID:
30256313
7.

Development of an opsonophagocytic killing assay for group a streptococcus.

Jones S, Moreland NJ, Zancolli M, Raynes J, Loh JMS, Smeesters PR, Sriskandan S, Carapetis JR, Fraser JD, Goldblatt D.

Vaccine. 2018 Jun 18;36(26):3756-3763. doi: 10.1016/j.vaccine.2018.05.056.

8.

Protein adhesins as vaccine antigens for Group A Streptococcus.

Raynes JM, Young PG, Proft T, Williamson DA, Baker EN, Moreland NJ.

Pathog Dis. 2018 Mar 1;76(2). doi: 10.1093/femspd/fty016. Review.

PMID:
29718270
9.

Group A Streptococcus pharyngitis and pharyngeal carriage: A meta-analysis.

Oliver J, Malliya Wadu E, Pierse N, Moreland NJ, Williamson DA, Baker MG.

PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006335. doi: 10.1371/journal.pntd.0006335. eCollection 2018 Mar. Review.

10.

The novel Group A Streptococcus antigen SpnA combined with bead-based immunoassay technology improves streptococcal serology for the diagnosis of acute rheumatic fever.

Hanson-Manful P, Whitcombe AL, Young PG, Atatoa Carr PE, Bell A, Didsbury A, Mitchell EA, Dunbar PR, Proft T, Moreland NJ.

J Infect. 2018 Apr;76(4):361-368. doi: 10.1016/j.jinf.2017.12.008. Epub 2017 Dec 18.

PMID:
29269013
11.

Group G Streptococcus Induces an Autoimmune Carditis Mediated by Interleukin 17A and Interferon γ in the Lewis Rat Model of Rheumatic Heart Disease.

Sikder S, Williams NL, Sorenson AE, Alim MA, Vidgen ME, Moreland NJ, Rush CM, Simpson RS, Govan BL, Norton RE, Cunningham MW, McMillan DJ, Sriprakash KS, Ketheesan N.

J Infect Dis. 2018 Jun 20;218(2):324-335. doi: 10.1093/infdis/jix637.

PMID:
29236994
12.

Clinical development strategy for a candidate group A streptococcal vaccine.

Schödel F, Moreland NJ, Wittes JT, Mulholland K, Frazer I, Steer AC, Fraser JD, Carapetis J.

Vaccine. 2017 Apr 11;35(16):2007-2014. doi: 10.1016/j.vaccine.2017.02.060. Epub 2017 Mar 16. Review.

PMID:
28318768
13.

Acute Rheumatic Fever After Group A Streptococcus Pyoderma and Group G Streptococcus Pharyngitis.

O'Sullivan L, Moreland NJ, Webb RH, Upton A, Wilson NJ.

Pediatr Infect Dis J. 2017 Jul;36(7):692-694. doi: 10.1097/INF.0000000000001558.

PMID:
28121967
14.

Development of a high-throughput opsonophagocytic assay for the determination of functional antibody activity against Streptococcus pyogenes using bioluminescence.

Lorenz N, Loh JM, Moreland NJ, Proft T.

J Microbiol Methods. 2017 Mar;134:58-61. doi: 10.1016/j.mimet.2017.01.010. Epub 2017 Jan 21.

PMID:
28115206
15.

Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.

Williamson DA, Smeesters PR, Steer AC, Morgan J, Davies M, Carter P, Upton A, Tong SY, Fraser J, Moreland NJ.

BMC Infect Dis. 2016 Oct 12;16(1):561.

16.

Invasive Group A Streptococcal Infections in Indigenous New Zealanders With Type 2 Diabetes.

Williamson DA, Moreland NJ, Jack S.

Clin Infect Dis. 2016 Nov 1;63(9):1268-1269. Epub 2016 Aug 29. No abstract available.

PMID:
27572100
17.

Serological Evidence of Immune Priming by Group A Streptococci in Patients with Acute Rheumatic Fever.

Raynes JM, Frost HR, Williamson DA, Young PG, Baker EN, Steemson JD, Loh JM, Proft T, Dunbar PR, Atatoa Carr PE, Bell A, Moreland NJ.

Front Microbiol. 2016 Jul 22;7:1119. doi: 10.3389/fmicb.2016.01119. eCollection 2016.

18.

Status of research and development of vaccines for Streptococcus pyogenes.

Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, Mulholland EK, Schodel F, Smeesters PR.

Vaccine. 2016 Jun 3;34(26):2953-2958. doi: 10.1016/j.vaccine.2016.03.073. Epub 2016 Mar 29.

19.

Development of Group A streptococcal vaccines: an unmet global health need.

Sheel M, Moreland NJ, Fraser JD, Carapetis J.

Expert Rev Vaccines. 2016;15(2):227-38. doi: 10.1586/14760584.2016.1116946. Epub 2015 Dec 3. Review.

PMID:
26559880
20.

M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand.

Williamson DA, Smeesters PR, Steer AC, Steemson JD, Ng AC, Proft T, Fraser JD, Baker MG, Morgan J, Carter PE, Moreland NJ.

J Clin Microbiol. 2015 Nov;53(11):3618-20. doi: 10.1128/JCM.02129-15. Epub 2015 Aug 19.

21.

Increasing incidence of invasive group A streptococcus disease in New Zealand, 2002-2012: a national population-based study.

Williamson DA, Morgan J, Hope V, Fraser JD, Moreland NJ, Proft T, Mackereth G, Lennon D, Baker MG, Carter PE.

J Infect. 2015 Feb;70(2):127-34. doi: 10.1016/j.jinf.2014.09.001. Epub 2014 Sep 20.

PMID:
25246363
22.

Survey of the bp/tee genes from clinical group A streptococcus isolates in New Zealand - implications for vaccine development.

Steemson JD, Moreland NJ, Williamson D, Morgan J, Carter PE, Proft T.

J Med Microbiol. 2014 Dec;63(Pt 12):1670-8. doi: 10.1099/jmm.0.080804-0. Epub 2014 Sep 4.

PMID:
25190737
23.

Crystal structure of PhnF, a GntR-family transcriptional regulator of phosphate transport in Mycobacterium smegmatis.

Gebhard S, Busby JN, Fritz G, Moreland NJ, Cook GM, Lott JS, Baker EN, Money VA.

J Bacteriol. 2014 Oct;196(19):3472-81. doi: 10.1128/JB.01965-14. Epub 2014 Jul 21.

24.

Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop.

Moreland NJ, Waddington CS, Williamson DA, Sriskandan S, Smeesters PR, Proft T, Steer AC, Walker MJ, Baker EN, Baker MG, Lennon D, Dunbar R, Carapetis J, Fraser JD.

Vaccine. 2014 Jun 24;32(30):3713-20. doi: 10.1016/j.vaccine.2014.05.017. Epub 2014 May 14.

PMID:
24837510
25.

Structural conservation, variability, and immunogenicity of the T6 backbone pilin of serotype M6 Streptococcus pyogenes.

Young PG, Moreland NJ, Loh JM, Bell A, Atatoa Carr P, Proft T, Baker EN.

Infect Immun. 2014 Jul;82(7):2949-57. doi: 10.1128/IAI.01706-14. Epub 2014 Apr 28.

26.

Identification of dengue-specific human antibody fragments using phage display.

Tay MY, Lee CC, Vasudevan SG, Moreland NJ.

Methods Mol Biol. 2014;1138:161-73. doi: 10.1007/978-1-4939-0348-1_11.

PMID:
24696337
27.

Molecular epidemiology of group A streptococcus from pharyngeal isolates in Auckland, New Zealand, 2013.

Williamson DA, Moreland NJ, Carter P, Upton A, Morgan J, Proft T, Lennon D, Baker MG, Dunbar R, Fraser JD.

N Z Med J. 2014 Jan 24;127(1388):55-60.

PMID:
24481387
28.

Can soluble adhesion molecules accurately predict carditis in acute rheumatic fever?

Moreland NJ, Wilson NJ.

Pediatr Cardiol. 2014 Mar;35(3):556-7. doi: 10.1007/s00246-014-0866-x. Epub 2014 Jan 19. No abstract available.

PMID:
24442265
29.

Identification and molecular characterization of human antibody fragments specific for dengue NS5 protein.

Zhao Y, Moreland NJ, Tay MY, Lee CC, Swaminathan K, Vasudevan SG.

Virus Res. 2014 Jan 22;179:225-30. doi: 10.1016/j.virusres.2013.11.010. Epub 2013 Nov 18.

PMID:
24262074
30.

Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.

Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, Vasudevan SG, Jans DA.

Antiviral Res. 2013 Sep;99(3):301-6. doi: 10.1016/j.antiviral.2013.06.002. Epub 2013 Jun 14.

PMID:
23769930
31.

Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors.

Takahashi H, Takahashi C, Moreland NJ, Chang YT, Sawasaki T, Ryo A, Vasudevan SG, Suzuki Y, Yamamoto N.

Antiviral Res. 2012 Dec;96(3):305-14. doi: 10.1016/j.antiviral.2012.09.023. Epub 2012 Oct 13.

PMID:
23072882
32.

A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.

Chan AH, Tan HC, Chow AY, Lim AP, Lok SM, Moreland NJ, Vasudevan SG, MacAry PA, Ooi EE, Hanson BJ.

PLoS One. 2012;7(4):e33451. doi: 10.1371/journal.pone.0033451. Epub 2012 Apr 3.

33.

Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.

Moreland NJ, Susanto P, Lim E, Tay MY, Rajamanonmani R, Hanson BJ, Vasudevan SG.

Int J Mol Sci. 2012;13(3):2618-35. doi: 10.3390/ijms13032618. Epub 2012 Feb 27.

34.

Expression and immunoaffinity purification of recombinant dengue virus 2 NS1 protein as a cleavable SUMOstar fusion.

Rozen-Gagnon K, Moreland NJ, Ruedl C, Vasudevan SG.

Protein Expr Purif. 2012 Mar;82(1):20-5. doi: 10.1016/j.pep.2011.11.003. Epub 2011 Nov 11.

PMID:
22100526
35.

Monoclonal antibodies against dengue NS2B and NS3 proteins for the study of protein interactions in the flaviviral replication complex.

Moreland NJ, Tay MY, Lim E, Rathore AP, Lim AP, Hanson BJ, Vasudevan SG.

J Virol Methods. 2012 Jan;179(1):97-103. doi: 10.1016/j.jviromet.2011.10.006. Epub 2011 Oct 20.

PMID:
22040846
36.

Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target.

Phong WY, Moreland NJ, Lim SP, Wen D, Paradkar PN, Vasudevan SG.

Biosci Rep. 2011 Oct;31(5):399-409. doi: 10.1042/BSR20100142.

PMID:
21329491
37.

High affinity human antibody fragments to dengue virus non-structural protein 3.

Moreland NJ, Tay MY, Lim E, Paradkar PN, Doan DN, Yau YH, Geifman Shochat S, Vasudevan SG.

PLoS Negl Trop Dis. 2010 Nov 9;4(11):e881. doi: 10.1371/journal.pntd.0000881.

38.

Making sense of a missense mutation: characterization of MutT2, a Nudix hydrolase from Mycobacterium tuberculosis, and the G58R mutant encoded in W-Beijing strains of M. tuberculosis.

Moreland NJ, Charlier C, Dingley AJ, Baker EN, Lott JS.

Biochemistry. 2009 Feb 3;48(4):699-708. doi: 10.1021/bi8009554.

PMID:
19115962
39.
40.

A new Gateway vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis.

Goldstone RM, Moreland NJ, Bashiri G, Baker EN, Shaun Lott J.

Protein Expr Purif. 2008 Jan;57(1):81-7. Epub 2007 Sep 14.

PMID:
17949993
41.

A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis.

Kendall SL, Withers M, Soffair CN, Moreland NJ, Gurcha S, Sidders B, Frita R, Ten Bokum A, Besra GS, Lott JS, Stoker NG.

Mol Microbiol. 2007 Aug;65(3):684-99.

42.
43.

Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.

Moreland NJ, Illand M, Kim YT, Paul J, Brown R.

Cancer Res. 1999 May 1;59(9):2102-6.

44.

Resistance to gentamicin: a growing concern.

Siebert WT, Moreland NJ, Williams TW Jr.

South Med J. 1977 Mar;70(3):289-92.

PMID:
322294

Supplemental Content

Loading ...
Support Center